{"schema_version":"secwatch.filing_event.v1","accession":"0001835268-25-000051","form_type":"8-K","ticker":"CNTB","cik":"0001835268","company_name":"Connect Biopharma Holdings Ltd","filed_at":"2025-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.225182+00:00","generated_at":"2026-05-17T13:59:29.587344+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Connect Biopharma Q2 net loss $12.9M; cash $71.8M; ADR program termination planned","bullets":["Net loss $12.9M ($0.23) vs net income $14.8M ($0.27) in Q2 2024; revenue $48K vs $24.1M.","Cash $71.8M expected to fund operations into 2027; R&D $8.8M up from $5.3M on Phase 2 trials.","Phase 2 Seabreeze STAT asthma/COPD studies recruiting; topline data expected H1 2026.","Simcere submitted NDA in China for rademikibart (AD); Connect eligible for up to $110M milestones.","Plans to terminate ADR program by Sep 2, 2025; ordinary shares to list on Nasdaq under CNTB."],"urls":{"canonical":"https://secwatch.observer/filing/0001835268-25-000051","json":"https://secwatch.observer/filing/0001835268-25-000051.json","markdown":"https://secwatch.observer/filing/0001835268-25-000051.md","text":"https://secwatch.observer/filing/0001835268-25-000051.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835268/000183526825000051/0001835268-25-000051-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835268/000183526825000051/cntb-20250813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:59:29.587344+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}